AGF Investments Inc. Takes $443,000 Position in Alexion Pharmaceuticals, Inc. (ALXN)

AGF Investments Inc. purchased a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the fourth quarter, HoldingsChannel reports. The fund purchased 4,552 shares of the biopharmaceutical company’s stock, valued at approximately $443,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. NuWave Investment Management LLC raised its position in Alexion Pharmaceuticals by 851.9% during the fourth quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 460 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Alexion Pharmaceuticals in the fourth quarter valued at approximately $68,000. First Hawaiian Bank bought a new position in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $102,000. We Are One Seven LLC bought a new position in shares of Alexion Pharmaceuticals in the fourth quarter valued at approximately $79,000. Finally, Shine Investment Advisory Services Inc. raised its position in shares of Alexion Pharmaceuticals by 114.1% in the fourth quarter. Shine Investment Advisory Services Inc. now owns 897 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 478 shares during the period. 92.55% of the stock is owned by institutional investors and hedge funds.

Get Alexion Pharmaceuticals alerts:

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 3,244 shares of Alexion Pharmaceuticals stock in a transaction on Monday, December 31st. The shares were sold at an average price of $95.85, for a total transaction of $310,937.40. Following the sale, the chief executive officer now owns 150,696 shares in the company, valued at $14,444,211.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total transaction of $252,000.00. Following the sale, the chief accounting officer now owns 5,020 shares in the company, valued at approximately $632,520. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,488 shares of company stock worth $873,875. 4.35% of the stock is currently owned by corporate insiders.

Shares of Alexion Pharmaceuticals stock opened at $135.33 on Friday. The firm has a market capitalization of $30.24 billion, a PE ratio of 19.09, a P/E/G ratio of 0.97 and a beta of 1.56. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.48 and a current ratio of 2.88. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.54. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. Alexion Pharmaceuticals’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the company posted $1.48 earnings per share. On average, sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.51 earnings per share for the current year.

A number of equities analysts have recently commented on ALXN shares. Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, December 30th. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 8th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 22nd. Oppenheimer set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 14th. Finally, Raymond James reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Friday, December 21st. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $160.63.

WARNING: “AGF Investments Inc. Takes $443,000 Position in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4188611/agf-investments-inc-takes-443000-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Recommended Story: What is the float in trading stocks?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).